earnings
confidence high
sentiment neutral
materiality 0.70
Eyenovia Reports Q1 2025 Financial Results, Provides Merger and Optejet Development Update
HYPERION DEFI, INC.
2025-Q1 EPS
reported -$1.59
vs consensus -$9.79
▲ beat
(+83.8%)
- Net loss narrowed to $3.5 million ($1.59 per share) versus $10.9 million ($18.75 per share) in Q1 2024.
- Continuing merger negotiations with Betaliq; binding exclusivity extended to June 7, 2025.
- Optejet user-filled device on track to file for FDA device approval in September 2025.
- Cash burn reduced by approximately 70% versus prior year; debt restructuring with Avenue Capital defers payments to October 2025.
- Unrestricted cash and equivalents totaled $3.9 million as of March 31, 2025.
item 2.02item 9.01